IL10 and myeloid sarcoma: Finally, we suggest that intravenous administration of hUCSC-EVs alleviate induce-EAE by reducing the pro-inflammatory cytokines, such as IL-17a, TNF-α and IFN-γ, and increasing the anti-inflammatory cytokines, IL-10 and IL-4, and also decrease the leukocyte infiltration in an animal model of MS.